Company / Cash & Equivalents
ENANTA PHARMACEUTICALS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$32.3M
FY2025
5-year range
$32.3M / $85.4M
FY2021-FY2025
Trend
-13.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $22M in FY2017 to $87M in FY2020.
Based on SEC 10-K filings.
$32M in FY2025 with a 5-year CAGR of -18.0%.
Declined from $85M to $32M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -9.8%
- 5-Year CAGR
- -18.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -18.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 13.3% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.3M | -13.3% |
| FY2024 | $37.2M | -56.4% |
| FY2023 | $85.4M | +94.1% |
| FY2022 | $44.0M | -23.1% |
| FY2021 | $57.2M | -34.3% |
| FY2020 | $87.1M | +70.1% |
| FY2019 | $51.2M | -19.8% |
| FY2018 | $63.9M | +194.1% |
| FY2017 | $21.7M | -29.2% |
| FY2016 | $30.7M | +246.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026